Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer

Annals of Oncology

Volumn 27, Issue 1, 2016, Pages 1953-1958

  Mansfield, A S ^a   Aubry, M C ^a   Moser, J C ^a   Harrington, S M ^a   Dronca, R S ^a   Park, S S ^a   Dong, H ^a  

^a MAYO CLINIC   (United States)

Author keywords

Heterogeneity; Lung cancer; Metastasis; PD L1; Tumor immunology

Indexed keywords

CD3 ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; TUMOR MARKER;

ANTIGEN EXPRESSION; ARTICLE; BRAIN METASTASIS; COHORT ANALYSIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPATIOTEMPORAL ANALYSIS; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR CLASSIFICATION; TUMOR MICROENVIRONMENT; ADULT; AGED; BRAIN TUMOR; CLINICAL DECISION MAKING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; SECONDARY;

ADULT; AGED; B7-H1 ANTIGEN; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CD3 COMPLEX; CLINICAL DECISION-MAKING; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; TUMOR MICROENVIRONMENT;

EID: 85014431333     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw289     Document Type: Article

References (28)

1. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627-1639
2. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123-135
3. Herbst RS, Baas P, Kim DW et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387: 1540-1550
4. Mansfield AS, Dong H. Implications of programmed cell death 1 ligand 1 heterogeneity in the selection of patients with non-small cell lung cancer to receive immunotherapy. Clin Pharmacol Ther 2016 May [epub ahead of print], doi: 10.1002/cpt.360
5. Leventakos K, Mansfield AS. Reflections on immune checkpoint inhibition in nonsmall cell lung cancer. Transl Lung Cancer Res 2014; 3: 411-413
6. Hansen AR, Siu LL. PD-L1 testing in cancer: challenges in companion diagnostic development. JAMA Oncol 2016; 2: 15-16
7. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, costimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5: 1365-1369
8. Dong H, Strome SE, Salomao DR et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8: 793-800
9. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-264
10. Parsa AT, Waldron JS, Panner A et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007; 13: 84-88
11. Akbay EA, Koyama S, Carretero J et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013; 3: 1355-1363
12. Chen N, Fang W, Zhan J et al. Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation. J Thorac Oncol 2015; 10: 910-923
13. AtefiM, Avramis E, Lassen A et al. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res 2014; 20: 3446-3457
14. Taube JM, Anders RA, Young GD et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4: 127ra137
15. Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res 2015; 75: 2139-2145
16. McLaughlin J, Han G, Schalper KA et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol 2016; 2: 46-54
17. Ilie M, Long-Mira E, Bence C et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol 2016; 27: 147-153
18. Mansfield AS, Murphy SJ, Peikert T et al. Heterogeneity of programmed cell deathligand 1 expression in multifocal lung cancer. Clin Cancer Res 2016; 22: 2177-2182
19. Mansfield AS, Roden AC, Peikert T et al. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol 2014; 9: 1036-1040
20. Thompson RH, Dong H, Kwon ED. Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res 2007; 13: 709s-715s
21. Thompson RH, Kuntz SM, Leibovich BC et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006; 66: 3381-3385
22. Krzywinski M, Schein J, Birol I et al. Circos: an information aesthetic for comparative genomics. Genome Res 2009; 19: 1639-1645
23. Konishi J, Yamazaki K, Azuma M et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 2004; 10: 5094-5100
24. Boland JM, Kwon ED, Harrington SM et al. Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. Clin Lung Cancer 2013; 14: 157-163
25. Kim MY, Koh J, Kim S et al. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: comparison with tumor-infiltrating T cells and the status of oncogenic drivers. Lung Cancer 2015; 88: 24-33
26. Callea M, Albiges L, Gupta M et al. Differential expression of PD-L1 between primary and metastatic sites in clear-cell renal cell carcinoma. Cancer Immunol Res 2015; 3: 1158-1164
27. Kluger HM, Zito CR, Barr ML et al. Characterization of PD-L1 expression and associated T-cell infiltrates in metastatic melanoma samples from variable anatomic sites. Clin Cancer Res 2015; 21: 3052-3060
28. Dronca RS, Liu X, Harrington SM et al. T cell Bim levels reflect responses to anti-PD-1 cancer therapy. JCI Insight 2016; 1(6): e86014